Findings suggest that underlying inflammation may be the cause of increased rates of CV events for patients with IBD.
Study Reveals Racial Disparities in Treatment of Inflammatory Bowel Disease
New Cleveland Clinic research shows a troubling disparity in Black patients’ access to advanced inflammatory bowel disease therapies when compared with white patients. This lack of access to advanced treatments can have severe health consequences for patients, including more complications and hospitalizations.
Biologic Therapies Are Lowering the Rate of Abdominal Surgeries for Crohn’s Disease
A team of clinicians, statisticians and computer analysts came together to examine the impact of biological therapies in the treatment of adult and pediatric Crohn’s disease.
Higher Biologic Use in Crohn’s Disease Associated With Lower Abdominal Surgery Rate
A study of patients treated for Crohn’s disease at Cleveland Clinic found that rates of abdominal surgery were significantly lower in patients who received biologics for six months or more, compared with those treated for less than six months. In this article, Jacob Kurowski, MD, discusses his findings.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Balancing the Benefits of Biologic Therapy for Autoimmune Disease Against the Risks of Mycobacterial Infections
Tumor necrosis factor-α inhibitors (TNFis) have transformed care for rheumatoid arthritis and other autoimmune diseases, but they also are associated with higher risks of serious and opportunistic infections than traditional disease-modifying antirheumatic drugs. In this article, Cassandra Calabrese, DO, discusses balancing the benefits of biologic therapies with the risks of infection.
TARGET-IBD Findings Demonstrate Need for Objective Evaluation Prior to Therapy Changes
Clinicians do not administer reactive TDM or objective disease activity assessments prior to making changes in biologic therapies in almost a third of patients with IBD.
Advances in Biologic Therapies for IMIDs
After two decades of using biologics for IMIDs, we now have an armamentarium, including five drugs and a number of biosimilars, that continues to grow at a record pace.
Treat with Biologics? You Need This On-Demand CME
Whether you plan to complete the entire series or prefer to pick a handful of individual webcasts most relevant to your practice, don’t miss this complimentary educational opportunity.
Biologic Therapies for Metabolic Bone Disease
Denosumab and romosozumab work on different pathways but offer new options for patients with low bone mass as primary therapy and for those unresponsive to or contraindicated for bisphosphonates.
Deadly but Preventable: HBV Reactivation After Immunosuppressive Treatment
Individuals with clinically unapparent HBV and concomitant immune-mediated inflammatory diseases (IMIDs) (e.g., rheumatoid arthritis, psoriasis, inflammatory bowel disease and others) are particularly vulnerable to HBV reactivation when immunosuppressed.